Dogwood Therapeutics Inc (DWTX)

Over the past six months (October 2025 - April 2026), Dogwood Therapeutics' stock price has decreased significantly. In December 2025, the company announced positive interim Phase 2b clinical trial results for Halneuron® in chemotherapy-induced neuropathic pain (CINP). In January 2026, the company announced financing of up to $26.8 million to progress Halneuron® through Phase 2b development. In February 2026, Dogwood Therapeutics announced 50% enrollment in its ongoing Halneuron® Phase 2b trial. In March 2026, the company reported its Fourth Quarter and Full Year 2025 Financial Results. In November 2025, Dogwood announced the enrollment of the first 100 patients in the Halneuron® Phase 2b trial. In December 2025, Dogwood Therapeutics filed new synthetic Halneuron® intellectual property protection. In November 2025, Dogwood Therapeutics reported its Third Quarter 2025 Financial Results.

Dogwood Therapeutics, Inc. exhibits distinct seasonal tendencies. January has historically been the strongest month, while February tends to be the weakest month. The seasonal pattern has a consistency score of 65 (Good), suggesting a relatively reliable seasonal trend. Over a full calendar year, DWTX has an average annual return of 28.33% with an overall monthly win rate of 35.8%.

Dogwood Therapeutics, Inc. (DWTX) is a development-stage biopharmaceutical company focused on advancing novel therapeutics to treat pain, neuropathy, and fatigue-related disorders. Its pipeline includes Halneuron®, a non-opioid sodium channel blocker in Phase 2b development for pain; IMC-1, an antiviral therapy that has completed Phase 2b clinical trials for fibromyalgia; IMC-2, intended for Long-COVID treatment; and SP16 IV, in early Phase 1 development for neuropathy. The company was formerly known as Virios Therapeutics, Inc. and changed its name in October 2024.

Dogwood Therapeutics, Inc. is headquartered in Alpharetta, Georgia, United States, and conducts clinical trials for Halneuron® at approximately 25 to 30 U.S. sites. CK Life Sciences Int'l., (Holdings) Inc., its largest shareholder, is listed on the Hong Kong Stock Exchange, indicating an international financial connection. Wex Pharmaceuticals Inc., which developed Halneuron®, is based in Vancouver, British Columbia, Canada. The company identifies a significant global market opportunity for CINP, with North America, Europe, and Asia-Pacific each representing substantial portions of this market.

Direct information explicitly detailing "brand reputation" or "public sentiment" for Dogwood Therapeutics, Inc. in the past year is not readily available. However, analyst ratings suggest a generally positive outlook from financial experts. Insider sentiment is positive, with insiders buying shares. Positive clinical trial progress and financing announcements would likely enhance the company's scientific and clinical reputation. The decrease in stock price could negatively impact investor perception.

Dogwood Therapeutics, Inc. has a mix of institutional and individual owners. Major institutional shareholders include Vanguard Group Inc, Geode Capital Management, Llc, and Marshall Wace, Llp. Sealbond Ltd is the largest individual shareholder, owning 73.84% of the company. Insider ownership stands at 43.80%, comprising 840.75K shares out of 1.92 million total outstanding as of March 23, 2026.